These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8471775)

  • 1. A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.
    Bergeron RJ; Streiff RR; Creary EA; Daniels RD; King W; Luchetta G; Wiegand J; Moerker T; Peter HH
    Blood; 1993 Apr; 81(8):2166-73. PubMed ID: 8471775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
    Bergeron RJ; Streiff RR; Wiegand J; Luchetta G; Creary EA; Peter HH
    Blood; 1992 Apr; 79(7):1882-90. PubMed ID: 1558978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.
    Bergeron RJ; Wiegand J; Bharti N; McManis JS
    J Med Chem; 2012 Aug; 55(16):7090-103. PubMed ID: 22889170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation of desferrithiocin metabolism.
    Bergeron RJ; Wollenweber M; Wiegand J
    J Med Chem; 1994 Sep; 37(18):2889-95. PubMed ID: 8071936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desferrithiocin analogues and nephrotoxicity.
    Bergeron RJ; Wiegand J; McManis JS; Bharti N; Singh S
    J Med Chem; 2008 Oct; 51(19):5993-6004. PubMed ID: 18788724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the iron-clearing properties of parabactin and desferrioxamine.
    Bergeron R; Streiff RR; King W; Daniels RD; Wiegand J
    Blood; 1993 Oct; 82(8):2552-7. PubMed ID: 8400302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative evaluation of iron clearance models.
    Bergeron RJ; Streiff RR; Wiegand J; Vinson JR; Luchetta G; Evans KM; Peter H; Jenny HB
    Ann N Y Acad Sci; 1990; 612():378-93. PubMed ID: 2127168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.
    Bergeron RJ; Bharti N; Wiegand J; McManis JS; Singh S; Abboud KA
    J Med Chem; 2010 Apr; 53(7):2843-53. PubMed ID: 20232803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.
    Bergeron RJ; Wiegand J; McManis JS; McCosar BH; Weimar WR; Brittenham GM; Smith RE
    J Med Chem; 1999 Jul; 42(13):2432-40. PubMed ID: 10395484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-human primate model for the study of oral iron chelators.
    Wolfe LC; Nicolosi RJ; Renaud MM; Finger J; Hegsted M; Peter H; Nathan DG
    Br J Haematol; 1989 Jul; 72(3):456-61. PubMed ID: 2765410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity.
    Bergeron RJ; Wiegand J; Bharti N; McManis JS; Singh S
    Biometals; 2011 Apr; 24(2):239-58. PubMed ID: 21103911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
    Dexter DT; Ward RJ; Florence A; Jenner P; Crichton RR
    Biochem Pharmacol; 1999 Jul; 58(1):151-5. PubMed ID: 10403528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates.
    Bergeron RJ; McManis JS; Bussenius J; Brittenham GM; Wiegand J
    J Med Chem; 1999 Jul; 42(15):2881-6. PubMed ID: 10425097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
    Bergeron RJ; Wiegand J; Dionis JB; Egli-Karmakka M; Frei J; Huxley-Tencer A; Peter HH
    J Med Chem; 1991 Jul; 34(7):2072-8. PubMed ID: 2066978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.
    Bergeron RJ; Wiegand J; Weimar WR; Vinson JR; Bussenius J; Yao GW; McManis JS
    J Med Chem; 1999 Jan; 42(1):95-108. PubMed ID: 9888836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
    Bergeron RJ; Wiegand J; Brittenham GM
    Blood; 1999 Jan; 93(1):370-5. PubMed ID: 9864183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desferrithiocin analogue based hexacoordinate iron(III) chelators.
    Bergeron RJ; Huang G; Weimar WR; Smith RE; Wiegand J; McManis JS
    J Med Chem; 2003 Jan; 46(1):16-24. PubMed ID: 12502356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desferrithiocin and desferrioxamine B. Cellular pharmacology and storage iron mobilization.
    Jin Y; Baquet A; Florence A; Crichton RR; Schneider YJ
    Biochem Pharmacol; 1989 Oct; 38(19):3233-40. PubMed ID: 2818622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partition-variant desferrithiocin analogues: organ targeting and increased iron clearance.
    Bergeron RJ; Wiegand J; McManis JS; Weimar WR; Park JH; Eiler-McManis E; Bergeron J; Brittenham GM
    J Med Chem; 2005 Feb; 48(3):821-31. PubMed ID: 15689166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators.
    Bergeron RJ; Wiegand J; Wollenweber M; McManis JS; Algee SE; Ratliff-Thompson K
    J Med Chem; 1996 Apr; 39(8):1575-81. PubMed ID: 8648596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.